[1] Thiocarlide has considerable antimycobacterial activity in vitro and is effective against multi-drug resistant strains of Mycobacterium tuberculosis.

[2] Isoxyl inhibits M. bovis with six hours of exposure, which is similar to isoniazid and ethionamide, two other prominent anti-TB drugs.

Unlike these two drugs, however, isoxyl also partially inhibits the synthesis of fatty acids.

[citation needed] Thiocarlide was developed by a Belgian company, Continental Pharma S.A. Belgo-Canadienne in Brussels, Belgium.

[citation needed] This antiinfective drug article is a stub.